 , which is conducting the review, will consider whether other treatments in same broader category of medicines, glucagon-like peptide-1 (GLP-1) receptor agonists, also need assessing. But initially, it will assess only the risks of using weight-loss medication that contains either semaglutide or liraglutide. An EMA official said: "The review is being carried out in the context of a signal procedure raised by the Icelandic Medicines Agency, following three case reports. "A signal is information on a new or known adverse event that is potentially caused by a medicine and that warrants further investigation. "The case reports included two cases of suicidal thoughts - one following the use of Saxenda and one after Ozempic. "One additional case reported thoughts of self-injury with Saxenda. "The EMA will communicate further when more information becomes available." Social media posts about people, often celebrities, shedding large amounts of weight has led to big demand for these types of treatment. Saxenda and Wegovy are approved and licensed for weight loss. Wegovy is not yet available in the UK - but the prime minister has said GPs in England may soon start offering it to some patients, as well as specialist weight-management clinics. Ozempic is for people with diabetes to help control blood sugar as well as weight but contains a lower dose of the same medicine, semaglutide, as Wegovy. An){kind=link}
Europe’s drugs regulator has told BBC News it is conducting a review of some weight-loss jabs after being alerted to a possible link to thoughts of suicide and self-harm among users.
Member state Iceland notified the European Medicines Agency after seeing three cases.
The safety assessment will look at Wegovy, Saxenda and similar drugs, such as Ozempic, that help curb appetite.
Product leaflets already list suicidal thoughts as a possible side effect.
Suicidal behaviour is not currently listed for these prescription drugs.